Ascendis Pharma A/S
NASDAQ:ASNDBiotechnology
-$0.05 today
- Market cap
- $17.73B
- Beta
- 0.39
- P/E (TTM)
- 24.5
- EPS (TTM)
- $8.21
Volume 0.57M
Average 0.64M
ASND Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Ascendis Pharma A/SNASDAQ: ASND
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q3 FY2026 selling, general & admin of €144.28M rose 29.2% year over year, behind the +52.7% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 17.3% from the prior quarter. Over 3 fiscal years it compounded at +26.4% a year.
Context
- Selling, general & admin amounted to 63.0% of revenue in FY2025, down 15.2 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 13 analysts of €7.36B (+1589.2%) for the fiscal year ending Dec 2026, a step up from the +53.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- €144.28M-17.3% QoQ
- Last fiscal yearDec 2025
- €435.92M+53.2% YoY
- LTMSep 2026
- €598.18M+52.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
EUR · from the income statement
- Latest · FY2025
- 435.92M EUR
- Year-over-year change
- +53.2%
- 4-year CAGR
- +28.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 435.92M | +53.2% |
| FY2024 | 2024-12-31 | 284.55M | +10.0% |
| FY2023 | 2023-12-31 | 258.79M | +19.9% |
| FY2022 | 2022-12-31 | 215.85M | +34.8% |
| FY2021 | 2021-12-31 | 160.18M | — |
Selling, General & Admin vs competitors
How ASND compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +52.7% is the 5th highest of 11, against a peer median of +36.6%.
- Selling, general & admin amounts to 49.5% of revenue for ASND, versus a peer median of 52.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $335.1B USD | +34325.1% | +15.8% | 32.6% | |
| LTM Sep 2026 | $1.43B USD | +24.9% | +15.4% | 38.5% | |
| LTM Jun 2026 | $893.59M USD | +58.5% | +38.2% | 78.5% | |
| LTM Jun 2026 | $730.9M USD | -1.6% | +14.5% | 23.2% | |
| LTM Sep 2026 | €598.18M EUR | +52.7% | +26.4% | 49.5% | |
| LTM Jun 2026 | $556.47M USD | +58.3% | +43.2% | 67.0% | |
| LTM Mar 2026 | $350.27M USD | +5.7% | +7.9% | 52.3% | |
| LTM Mar 2026 | $191.5M USD | +13.2% | +9.8% | 60.8% | |
| LTM Mar 2026 | $71.21M USD | +35.2% | +19.9% | 222.0% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $59.07M USD | +263.5% | +71.2% | — |
SEPNSepterna, Inc. | LTM Sep 2026 | $36.57M USD | +38.0% | — | 38.0% |
| Peer median (excluding ASND) | — | +36.6% | +15.8% | 52.3% | |
Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.78M | 51.17M | 266.72M | 363.64M | 691.71M |
| Cost of Revenue | 3.52M | 12.14M | 44.4M | 44.26M | 103.18M |
| Gross Profit | 4.26M | 39.04M | 222.32M | 319.38M | 588.53M |
| Gross Margin | 54.7% | 76.3% | 83.4% | 87.8% | 85.1% |
| Research & Development | 295.87M | 379.62M | 413.45M | 307M | 283.5M |
| Selling, General & Admin | 160.18M | 215.85M | 258.79M | 284.55M | 435.92M |
| Operating Expenses | 456.05M | 600.85M | 677.86M | 598.15M | 719.42M |
| Depreciation & Amortization | 15.39M | 17.96M | 18.91M | 17.71M | 17M |
| EBITDA | (364.64M) | (529.18M) | (411.17M) | (290.02M) | (109.8M) |
| EBITDA Margin | -4688.1% | -1034.1% | -154.2% | -79.8% | -15.9% |
| Operating Income | (451.79M) | (561.81M) | (455.54M) | (278.76M) | (130.89M) |
| Operating Margin | -5808.6% | -1097.9% | -170.8% | -76.7% | -18.9% |
| Interest Income | 692K | 7.43M | 16.86M | 14.36M | 14.7M |
| Interest Expense | 3.91M | 30.68M | 44.07M | 65.5M | 77.46M |
| Other Income / Expenses | 67.85M | (16M) | (18.6M) | (94.48M) | (73.37M) |
| Income Before Tax | (383.94M) | (577.82M) | (474.14M) | (373.24M) | (204.26M) |
| Pre-Tax Margin | -4936.3% | -1129.1% | -177.8% | -102.6% | -29.5% |
| Income Tax Expense | (367K) | 5.38M | 7.3M | 4.84M | 14.78M |
| Net Income | (383.58M) | (583.19M) | (481.45M) | (378.08M) | (219.03M) |
| Net Margin | -4931.6% | -1139.6% | -180.5% | -104.0% | -31.7% |
| EPS (Basic) | (7.00) | (10.40) | (8.55) | (6.53) | (3.62) |
| EPS (Diluted) | (7.00) | (10.40) | (8.55) | (6.53) | (3.62) |
| Weighted Avg Shares | 54.77M | 56.07M | 56.29M | 57.89M | 60.61M |
| Weighted Avg Shares (Diluted) | 54.77M | 56.07M | 56.29M | 57.89M | 60.61M |
Ascendis Pharma A/S
NASDAQ:ASND
Intrinsic Alpha fair value
Locked
Current Price
$270.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.